The tiny worm *C. elegans* is proving a big asset for Magnitude Biosciences Ltd, which just raised $1.7M to advance its work in non-invasive health assays. The company leverages its expertise in the nematode to provide quantified health outcome data for biotech, nutrition, and other industries.
Magnitude Biosciences' technology allows clients to prescreen compounds, find effective and safe concentration ranges, and test mutants in signaling pathways, significantly reducing the need for extensive mammal experiments in drug discovery pipelines. Their team specializes in designing customized C. elegans studies for aging research and integrating the worms into drug discovery.

















